Noma Hidetaka, Mimura Tatsuya, Yasuda Kanako, Shimura Masahiko
Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan.
Department of Ophthalmology, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan.
Br J Ophthalmol. 2017 Feb;101(2):180-185. doi: 10.1136/bjophthalmol-2015-307989. Epub 2016 Apr 12.
BACKGROUND/AIMS: Correlations among functional-morphological parameters, the aqueous flare value (an indicator of inflammation) and aqueous humour levels of cytokines/inflammatory factors were investigated in patients with branch retinal vein occlusion (BRVO) and macular oedema who received intravitreal ranibizumab injection (IRI) and were followed for 6 months.
Aqueous humour levels of 11 cytokines or growth inflammatory/factors were measured in 45 patients with BRVO and macular oedema who received IRI. Patients with recurrent macular oedema were given further IRI as needed. Aqueous humour levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR) and other cytokines/inflammatory factors were measured by the suspension array method. Aqueous flare values were measured with a laser flare metre and macular oedema was examined by optical coherence tomography.
There were significant correlations between the aqueous flare and the aqueous levels of sVEGFR-1, placental growth factor, monocyte chemoattractant protein 1, soluble intercellular adhesion molecule-1, interleukin (IL)-6 and IL-8. There were also significant correlations between the change of the aqueous flare and improvement of central macular thickness after 1 month, after 6 months and at the 1st recurrence. Furthermore, a significant correlation was noted between the change of the aqueous flare and improvement of best-corrected visual acuity at 6 months after IRI, but not at 1 month or at the 1st recurrence.
These findings suggest that the aqueous flare is associated with inflammatory factors/cytokines, and that the change of the aqueous flare value may influence the long-term prognosis in patients with BRVO receiving IRI therapy for macular oedema.
背景/目的：在接受玻璃体内注射雷珠单抗（IRI）并随访6个月的视网膜分支静脉阻塞（BRVO）合并黄斑水肿患者中，研究功能形态学参数、房水闪光值（炎症指标）与房水中细胞因子/炎症因子水平之间的相关性。
对45例接受IRI治疗的BRVO合并黄斑水肿患者测量11种细胞因子或生长/炎症因子的房水水平。复发性黄斑水肿患者根据需要接受进一步的IRI治疗。采用悬浮阵列法测量血管内皮生长因子（VEGF）、可溶性VEGF受体（sVEGFR）及其他细胞因子/炎症因子的房水水平。用激光闪光计测量房水闪光值，并用光学相干断层扫描检查黄斑水肿情况。
房水闪光与sVEGFR-1、胎盘生长因子、单核细胞趋化蛋白1、可溶性细胞间黏附分子-1、白细胞介素（IL）-6和IL-8的房水水平之间存在显著相关性。在1个月后、6个月后及首次复发时，房水闪光的变化与中心黄斑厚度的改善之间也存在显著相关性。此外，在IRI治疗6个月后，房水闪光的变化与最佳矫正视力的改善之间存在显著相关性，但在1个月时或首次复发时不存在这种相关性。
这些发现表明，房水闪光与炎症因子/细胞因子相关，房水闪光值的变化可能会影响接受IRI治疗黄斑水肿的BRVO患者的长期预后。
